Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and ...

Pfizer has escalated its fight for obesity biotech Metsera by filing suit against both Metsera and Novo Nordisk in the ...

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, ...

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novo Nordisk, with a price target of DKK540.00. The company’s shares closed yesterday at DKK324.94. Take ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk today and set a price target of DKK600.00. The company’s shares closed yesterday at DKK324.94. Take advantage of ...